Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03344458 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial
A Phase 3 study, sponsored by Ascendis Pharma A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 298
- Enrollment target
NCT03344458 is a Phase 3 study that has completed, run by Ascendis Pharma A/S. The registered enrollment target is 298 participants.
The verdict
NCT03344458, a Phase 3 study, has completed, sponsored by Ascendis Pharma A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 298 participants
- Enrollment target
Study Summary
A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial. Approximately 300 children (males and females) with GHD will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Poland, Bulgaria, Ukraine, Armenia, Russia and Australia.
Interventions
- DRUG TransCon hGH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2017-12-19 |
| Est. Completion | 2023-02-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03344458
The ClinicalTrials.gov registry entry for NCT03344458 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascendis Pharma A/S, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TransCon hGH is the first listed.
NCT03344458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03344458 about?
NCT03344458 is a clinical study titled "A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial". A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial. Approximately 300 children (males and females) with GHD will be included. All study participants wi...
What is the current status of trial NCT03344458?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 298 participants. The study started on 2017-12-19. Estimated completion is 2023-02-21.
What interventions are being tested in trial NCT03344458?
The interventions under investigation include: TransCon hGH (DRUG).
Who is sponsoring clinical trial NCT03344458?
This trial is sponsored by Ascendis Pharma A/S, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.